Sonic Healthcare Valuation

Is SHL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SHL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SHL (A$29.41) is trading below our estimate of fair value (A$53.8)

Significantly Below Fair Value: SHL is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for SHL?

Other financial metrics that can be useful for relative valuation.

SHL key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.1x
Enterprise Value/EBITDA16x
PEG Ratio1.9x

Price to Earnings Ratio vs Peers

How does SHL's PE Ratio compare to its peers?

The above table shows the PE ratio for SHL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average45.3x
ACL Australian Clinical Labs
35x24.4%AU$539.4m
RHC Ramsay Health Care
58.5x18.3%AU$12.9b
CAJ Capitol Health
41.6x38.7%AU$255.7m
HLA Healthia
46.1xn/aAU$252.1m
SHL Sonic Healthcare
27.9x14.5%AU$14.1b

Price-To-Earnings vs Peers: SHL is good value based on its Price-To-Earnings Ratio (27.9x) compared to the peer average (45.3x).


Price to Earnings Ratio vs Industry

How does SHL's PE Ratio compare vs other companies in the Global Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a19.9%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a19.9%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: SHL is expensive based on its Price-To-Earnings Ratio (27.9x) compared to the Global Healthcare industry average (21.9x).


Price to Earnings Ratio vs Fair Ratio

What is SHL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SHL PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio27.9x
Fair PE Ratio31.5x

Price-To-Earnings vs Fair Ratio: SHL is good value based on its Price-To-Earnings Ratio (27.9x) compared to the estimated Fair Price-To-Earnings Ratio (31.5x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SHL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$29.41
AU$30.71
+4.4%
9.0%AU$34.94AU$25.95n/a15
Mar ’25AU$29.15
AU$30.61
+5.0%
8.9%AU$34.05AU$25.95n/a15
Feb ’25AU$31.59
AU$33.43
+5.8%
7.3%AU$37.00AU$29.80n/a14
Jan ’25AU$32.08
AU$33.19
+3.4%
8.9%AU$39.00AU$29.00n/a15
Dec ’24AU$29.12
AU$33.01
+13.4%
10.1%AU$39.00AU$27.44n/a16
Nov ’24AU$29.03
AU$34.12
+17.5%
10.3%AU$40.00AU$27.44n/a16
Oct ’24AU$29.80
AU$34.21
+14.8%
10.1%AU$40.00AU$27.44n/a16
Sep ’24AU$32.20
AU$34.30
+6.5%
9.9%AU$40.00AU$27.44n/a17
Aug ’24AU$35.12
AU$35.62
+1.4%
10.8%AU$43.00AU$27.44n/a17
Jul ’24AU$35.57
AU$35.30
-0.8%
10.3%AU$41.00AU$27.44n/a17
Jun ’24AU$35.44
AU$35.20
-0.7%
11.4%AU$43.00AU$27.44n/a17
May ’24AU$35.80
AU$35.73
-0.2%
9.4%AU$43.00AU$30.00n/a15
Apr ’24AU$34.84
AU$34.33
-1.5%
10.9%AU$41.00AU$25.75n/a16
Mar ’24AU$32.04
AU$34.19
+6.7%
11.1%AU$41.00AU$25.75AU$29.1516
Feb ’24AU$31.32
AU$33.76
+7.8%
10.8%AU$43.00AU$25.75AU$31.5915
Jan ’24AU$29.97
AU$34.00
+13.4%
10.7%AU$43.00AU$25.75AU$32.0815
Dec ’23AU$31.80
AU$34.30
+7.9%
11.2%AU$43.00AU$25.75AU$29.1215
Nov ’23AU$33.05
AU$34.81
+5.3%
11.1%AU$42.00AU$25.75AU$29.0315
Oct ’23AU$30.58
AU$34.95
+14.3%
11.4%AU$42.00AU$25.75AU$29.8015
Sep ’23AU$33.72
AU$36.30
+7.7%
12.7%AU$48.00AU$29.46AU$32.2016
Aug ’23AU$35.40
AU$36.42
+2.9%
13.2%AU$48.00AU$29.46AU$35.1216
Jul ’23AU$32.94
AU$37.76
+14.6%
12.1%AU$48.00AU$29.46AU$35.5716
Jun ’23AU$36.62
AU$38.27
+4.5%
11.9%AU$48.00AU$29.46AU$35.4416
May ’23AU$36.73
AU$38.41
+4.6%
12.5%AU$48.00AU$29.46AU$35.8016
Apr ’23AU$35.27
AU$38.59
+9.4%
11.9%AU$48.00AU$29.46AU$34.8416
Mar ’23AU$34.69
AU$38.78
+11.8%
11.8%AU$48.00AU$29.46AU$32.0416

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.